Abstract
A first derivative synchronous spectrofluorimetric method has been developed and validated for simultaneous determination of telmisartan (TEL) and amlodipine besylate (AML) in combined tablet dosage form without any prior separation of components from the sample. TEL was determined at emission wavelength of 675 nm (zero-crossing wavelength point of AML). Similarly, AML was measured at 458 nm (zero-crossing wavelength point of TEL). The first derivative amplitude- concentration plots were rectilinear over the range of 4-14 ?g/ml for TEL and 1-6 ?g/ml for AML. The method was validated statistically as per ICH guidelines. Limit of detection (LOD) and quantification (LOQ) are reported. The % assay in commercial formulation was found to be in the range 99.60 100.22 and 98.40 99.80 for TEL and AML, respectively by the proposed method and % RSD values for precision and accuracy studies were found to be less than 2. The proposed method can be successfully applied for routine analysis of TEL and AML in tablets. Dhaka Univ. J. Pharm. Sci. 12(1): 35-40, 2013 (June) DOI: http://dx.doi.org/10.3329/dujps.v12i1.16298
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Dhaka University Journal of Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
